Infy
Infosys delivered a strong Q3 FY26 with constant currency revenue growth of 1.7% YoY and adjusted operating margin of 21.2%, expanding 20 bps sequentially.
Infy vs Biocon Q3 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Biocon
Biocon delivered a solid Q3 FY26 with group revenue of ₹4,173 crore (+9% YoY) and EBITDA of ₹951 crore (+21% YoY), driven by strong biosimilar margins (28% vs 21% last year) and generics growth of 24%.
Result Snapshot
Revenue₹45,479 Cr₹4,173 Cr
PAT₹6,666 Cr₹-52 Cr
EBITDA Margin21.2%20%
Sentimentbullishbullish
Key Quotes
We are witnessing six AI-led value pools emerging that could unlock a large incremental opportunity for us.
Q3 FY26 represents an important operational inflection point for Biocon. With major capex now largely behind us and operating leverage beginning to play out, we are progressing from a phase of balance sheet resilience into a cycle of sustainable growth, margin expansion and a cash flow-led value creation.